孚能科技(688567.SH):廣州基地預計近期實現部分產線投產並供貨
格隆匯3月14日丨孚能科技(688567.SH)在投資者互動平臺表示,公司贛州新能源和廣州基地均爲SPS先進產能,可實現大幅降本增效,目前贛州新能源部分產線已經投產並出貨,廣州基地預計近期實現部分產線投產並供貨,兩基地其餘產線將綜合考慮在手訂單出貨以及安裝調試節奏,逐條產線進行投產。從目前已投產產線看,產品良率與產能利用率呈快速提升態勢,公司將加快推進其餘產線的生產調試,縮短爬產週期,儘早實現達產。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.